Stocks
KalVista Pharmaceuticals, Inc.KALV
NASDAQHealthcareBiotechnology$16.94-2.53%
A clinical-stage biotechnology company developing small‑molecule therapies for diseases driven by excessive protease activity, with a primary focus on hereditary angioedema (HAE). Its lead program, sebetralstat, is an oral plasma kallikrein inhibitor designed for on‑demand treatment of HAE attacks, ...
Market Cap: $856.3M52W Range: $9.23 – $19.00
This page tracks all publicly disclosed congressional trades in KalVista Pharmaceuticals, Inc. (KALV), a company in the Healthcare sector. 1 member of Congress has disclosed trades in this stock, including 1 purchase and 0 sales. All data is sourced from STOCK Act Periodic Transaction Reports filed with the House and Senate disclosure offices.
Total Disclosures
1
Unique Politicians
1
Buys
1
Sells
0
Congressional Trading History
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2022-12-12 | Christopher L. Jacobs | buy | $1K – $15K |